Hemispherx Biopharma (HEB)
Hemispherx Biopharma Cash Operations: -3.02M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
HEB Cash Operations Rankings
| Overall | 20th percentile | 3456 of 4352 |
| Sector | 35th percentile | 323 of 501 in Healthcare |
| Industry | 61st percentile | 60 of 156 in Biotechnology |
HEB Cash Operations Range, Past 5 Years
| Minimum | -5.95M | Sep 2010 |
| Maximum | -0.20M | Jun 2010 |
| Average | -2.699M |
About Cash Operations
An item on a company's cash flow statement. Lists aggregate change in cash position resulting from operations. Includes the company's cash inflows and outflows from the company's core business operations.
Learn More
You may also be interested in these HEB related companies
HEB News
$HEB maybe Carter can put Ampligen in e-cigarettes now that it's 2012 since he already explored putting it in real cigarettes in the 1980's
about 22 days ago by HankHill
about 22 days ago by HankHill
Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2012
May 07, 4:35PM GlobeNewswire
May 07, 4:35PM GlobeNewswire
$heb ever hold a stock so you could laugh at it every day ? i have
about 40 days ago by roadkingtrdr
about 40 days ago by roadkingtrdr
Hemispherx Biopharma, Inc. to Host 2011 Year End Conference Call on Thursday, March 22, 2012
Mar 20, 8:30AM GlobeNewswire
Mar 20, 8:30AM GlobeNewswire
$HEB Cross over coming also a Triple top breakout at stockcharts.com on the P&F.
about 72 days ago by rtk
about 72 days ago by rtk
Hemispherx Publishes Data on the Bioactivity of Ampligen(R) in Chronic Fatigue Syndrome ("CFS")
Mar 19, 8:30AM GlobeNewswire
Mar 19, 8:30AM GlobeNewswire
$HEB , I am early but bot it this morning. loking for a nice pop
about 117 days ago by 3DTRADINGTRADER
about 117 days ago by 3DTRADINGTRADER
Hemispherx Biopharma Receives U.S. Patent Office Notification of Two New Patents Granted for Alferon(R) LDO
Jan 17, 8:30AM GlobeNewswire
Jan 17, 8:30AM GlobeNewswire
Hemispherx Biopharma (HEB) Recieves FDA Extension for NDA for Treatment of Chronic Fatigue Syndrome
Jan 11, 8:35AM Street Insider
Jan 11, 8:35AM Street Insider
$HEB shares up 14% following extension to modify NDA for treatment of CFS
about 140 days ago by Street_Insider
about 140 days ago by Street_Insider
Hemispherx Biopharma (HEB) Gets Extension from FDA for CFS NDA Modification
Jan 11, 8:31AM Street Insider
Jan 11, 8:31AM Street Insider
FDA Grants $HEB Extension in Its Pending New Drug Application for the Treatment of Chronic Fatigue
about 140 days ago by Benzinga
about 140 days ago by Benzinga
Hemispherx Biopharma Announces Further Adjournment on Proposal Number 4 From the 2011 Annual Meeting of Stockholders
Nov 09, 4:13PM GlobeNewswire
Nov 09, 4:13PM GlobeNewswire
Hemispherx Biopharma Announces Financial Results for the Three Months Ended September 30, 2011
Nov 09, 12:26PM GlobeNewswire
Nov 09, 12:26PM GlobeNewswire
Hemispherx Biopharma, Inc. to Host Conference Call on Chronic Fatigue Syndrome Progress Thursday, October 27, 2011
Oct 24, 10:22AM GlobeNewswire
Oct 24, 10:22AM GlobeNewswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| HEB | 0.278 | +0.01 | +2.96% | 36.67M |
| HEAT | 4.04 | +0.00 | +0.00% | 15.59M |
| HE | 27.47 | +0.27 | +0.99% | 2.617B |
| HDY | 0.80 | -0.09 | -10.12% | 148.49M |
| HDSN | 3.96 | +0.11 | +2.86% | 91.55M |
| HDNG | 9.89 | +0.15 | +1.54% | 113.67M |
| HDG | 38.28 | +0.12 | +0.32% | |
| HDB | 29.36 | +0.76 | +2.66% | 22.18B |
| HD | 49.78 | +0.34 | +0.69% | 75.39B |
| HCSG | 19.97 | +0.24 | +1.24% | 1.319B |
